A Novel Prognostic Indicator for Immunotherapy Response: Lymphocyte-to-Albumin (LA) Ratio Predicts Survival in Metastatic NSCLC Patients

Basit Öğe Kaydı
dc.authoridYILDIRIM, MAHMUT EMRE/0000-0002-5360-5949
dc.authoridDogan, Akif/0000-0003-4275-2414
dc.authoridISIK, DENIZ/0000-0003-4398-5148
dc.authoridOdabas, Hatice/0000-0002-5757-4705
dc.authoridKinikoglu, Oguzcan/0000-0001-5983-3291
dc.authoridCavdar, Eyyup/0000-0001-5885-3047
dc.authoridsurmeli, heves/0000-0003-1604-8466
dc.contributor.authorYildirim, Sedat
dc.contributor.authorDogan, Akif
dc.contributor.authorAkdag, Goncagul
dc.contributor.authorCavdar, Eyyup
dc.contributor.authorKinikoglu, Oguzcan
dc.contributor.authorOksuz, Sila
dc.contributor.authorYildiz, Hacer Sahika
dc.date.accessioned2024-10-29T17:59:20Z
dc.date.available2024-10-29T17:59:20Z
dc.date.issued2024
dc.departmentTekirdağ Namık Kemal Üniversitesi
dc.description.abstractObjective: Immunotherapies are commonly employed for the treatment of non-small-cell lung cancer (NSCLC). However, predictive biomarkers still need to be improved to predict responses to these agents. The lymphocyte-albumin (LA) laboratory index has not been evaluated before in this patient group. The aim of this study was to analyze the relation between the LA index and the survival rate of metastatic NSCLC patients who had immunotherapy after at least one round of chemotherapy. Methods: The research included 227 patients diagnosed with metastatic NSCLC, who were administered nivolumab after at least one round of chemotherapy. The LA index was calculated by multiplying lymphocyte count and albumin concentration. The optimal threshold values for the index were established by the examination of the ROC curve for both overall survival (OS) and progression-free survival (PFS). Oncological data were obtained retrospectively from patient files, and survival analyses were performed. Results: The median follow-up was 7.9 months. Progression was observed in 129 (56.9%) patients. A total of 97 (42.7%) patients died during the follow-up. The cutoff values of the LA index to predict OS and PFS were determined as 52.87 and 57.67, respectively. The low-LA group had significantly lowered OS and PFS compared to the high-LA group. LA was found to be an independent prognostic factor for PFS (hazard ratio 4.47; 95% confidence interval, 2.73-7.34; p < 0.001) and OS (hazard ratio 6.24; 95% confidence interval, 3.46-11.25; p < 0.001) in the multivariate regression analysis. Conclusions: In this study, we observed that the LA index independently predicts OS and PFS in immunotherapy-treated metastatic NSCLC patients. Its ease of application, low cost, and noninvasive nature make it a potential guide for clinicians in predicting treatment responses and survival.
dc.identifier.doi10.3390/cancers16142512
dc.identifier.issn2072-6694
dc.identifier.issue14en_US
dc.identifier.pmid39061152
dc.identifier.scopus2-s2.0-85199632342
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.3390/cancers16142512
dc.identifier.urihttps://hdl.handle.net/20.500.11776/14703
dc.identifier.volume16
dc.identifier.wosWOS:001278221500001
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherMdpi
dc.relation.ispartofCancers
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectnivolumab
dc.subjectLA index
dc.subjectNSCLC
dc.subjectimmunotherapy
dc.subjectprognostic factor
dc.subjectlung cancer
dc.titleA Novel Prognostic Indicator for Immunotherapy Response: Lymphocyte-to-Albumin (LA) Ratio Predicts Survival in Metastatic NSCLC Patients
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu